Quince Therapeutics (QNCX) Competitors $1.03 +0.01 (+0.98%) Closing price 04:00 PM EasternExtended Trading$1.00 -0.03 (-3.30%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. PRME, INMB, TLSA, MOLN, ELDN, CTMX, OGI, INBX, PRQR, and HURAShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Prime Medicine (PRME), INmune Bio (INMB), Tiziana Life Sciences (TLSA), Molecular Partners (MOLN), Eledon Pharmaceuticals (ELDN), CytomX Therapeutics (CTMX), Organigram (OGI), Inhibrx (INBX), ProQR Therapeutics (PRQR), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Prime Medicine INmune Bio Tiziana Life Sciences Molecular Partners Eledon Pharmaceuticals CytomX Therapeutics Organigram Inhibrx ProQR Therapeutics TuHURA Biosciences Quince Therapeutics (NASDAQ:QNCX) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is QNCX or PRME more profitable? Quince Therapeutics' return on equity of -53.27% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Prime Medicine N/A -107.87%-74.97% Do analysts recommend QNCX or PRME? Quince Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 676.70%. Prime Medicine has a consensus price target of $11.80, indicating a potential upside of 912.88%. Given Prime Medicine's higher probable upside, analysts clearly believe Prime Medicine is more favorable than Quince Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Prime Medicine 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility & risk, QNCX or PRME? Quince Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Does the media refer more to QNCX or PRME? In the previous week, Prime Medicine had 12 more articles in the media than Quince Therapeutics. MarketBeat recorded 18 mentions for Prime Medicine and 6 mentions for Quince Therapeutics. Prime Medicine's average media sentiment score of 0.02 beat Quince Therapeutics' score of -0.16 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in QNCX or PRME? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Comparatively, 23.5% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer QNCX or PRME? Prime Medicine received 21 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes9100.00% Underperform VotesNo VotesPrime MedicineOutperform Votes3065.22% Underperform Votes1634.78% Which has stronger valuation & earnings, QNCX or PRME? Quince Therapeutics has higher earnings, but lower revenue than Prime Medicine. Quince Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.39-0.74Prime Medicine$3.85M39.77-$198.13M-$1.61-0.72 SummaryPrime Medicine beats Quince Therapeutics on 9 of the 17 factors compared between the two stocks. Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.83M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.8330.5026.8419.71Price / SalesN/A400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book0.523.286.794.50Net Income-$31.39M-$72.17M$3.23B$248.18M7 Day Performance22.42%4.28%4.07%1.14%1 Month Performance-1.90%7.62%12.52%15.20%1 Year Performance19.77%-28.15%16.83%6.56% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.908 of 5 stars$1.03+1.0%$8.00+676.7%+13.4%$46.83MN/A-0.8360PRMEPrime Medicine3.7023 of 5 stars$1.34+3.1%$13.14+880.8%-84.4%$175.76M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionGap DownINMBINmune Bio1.9459 of 5 stars$7.64+9.6%$22.80+198.4%-31.6%$175.60M$14,000.00-3.5010Positive NewsGap DownTLSATiziana Life Sciences1.0779 of 5 stars$1.50-4.5%N/A+94.8%$175.27MN/A0.008MOLNMolecular Partners1.9518 of 5 stars$4.28+4.4%$12.00+180.4%+5.6%$172.81M$4.97M-1.99180News CoverageEarnings ReportAnalyst RevisionGap UpELDNEledon Pharmaceuticals2.1568 of 5 stars$2.87-0.7%$12.50+335.5%-1.9%$171.86MN/A-1.4310News CoveragePositive NewsEarnings ReportAnalyst RevisionCTMXCytomX Therapeutics4.2313 of 5 stars$2.13+129.4%$3.75+76.1%+7.3%$171.72M$138.10M12.53170Analyst RevisionGap DownHigh Trading VolumeOGIOrganigram0.2552 of 5 stars$1.28+8.5%N/A-32.2%$171.31M$166.12M-3.37860High Trading VolumeINBXInhibrx1.8879 of 5 stars$11.71+4.7%N/A-62.1%$169.51M$200,000.000.00166Earnings ReportPRQRProQR Therapeutics3.0806 of 5 stars$1.59-1.2%$8.75+450.3%-8.3%$167.29M$18.91M-4.97180HURATuHURA BiosciencesN/A$3.82-4.3%$12.67+231.6%N/A$166.86MN/A0.00N/ANews CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Prime Medicine Alternatives INmune Bio Alternatives Tiziana Life Sciences Alternatives Molecular Partners Alternatives Eledon Pharmaceuticals Alternatives CytomX Therapeutics Alternatives Organigram Alternatives Inhibrx Alternatives ProQR Therapeutics Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QNCX Stock Free QNCX Stock Alerts